JPRN-jRCTs041210030招募中2 期
PhaseII study of Atezolizumab in Combination With Carboplatin Plus Nab-Paclitaxel Chemotherapy in Performance Status 2 Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer
Murakami Haruyasu0 个研究点目标入组 20 人开始时间: 2021年6月10日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Patients with small cell lung cancer (NSCLC) confirmed histologically or cytologically.
- •2)Patients with stageIV, postoperative recurrence, or postchemoradiotherapy recurrence
- •3)Previously untreated patients.
- •Any postoperative chemotherapy or chemoradiotherapy given at least 6 months before enrollment in the present study is acceptable.
- •A driver genetic mutation positive patient (EGFR, ALK, ROS1,BRAF(V600E),MET, RET, or NTRK) will be eligible for enrollment if they have confirmed disease progression after at least one line of target therapy for each driver gene and no other prior systemic drug therapy.
- •4)Age of 20 years or older at the time of informed consent
- •5)ECOG performance status of 2
- •6)At least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) ver1.1.
- •7)The latest clinical laboratory test within 7 days prior to enrollment (it is eligible on the same day 1weeks before the enrolment day) meets the following all standard.
- •1. Neutrophil count >= 1500/mm3
- •2. Platelet count >= 10.0x10000/mm3
- •3. Haemoglobin >= 9.0g/dL
- •4. AST* <= 100IU/L
- •5. ALT* <= 100IU/L
- •6. Total bilirubin <= 1.5mg/dL
- •7. Creatinine <= 1.5mg/dL
- •8. SpO2 >= 90%(without oxygen administration)
- •*Patients with documented liver metastases: AST and/or ALT <=200IU/L
- •8)patients have a life expectancy of at least 12 weeks
- •9)Patients providing the written informed consent
排除标准
- •1)Patients with severe complication, such as cerebrovascular disease, transient ischemic attacks, symptomatic heart failure, uncontrollable angina pectoris, or myocardial infarction within 1 year.
- •2)Patients with active double cancer (synchronous double cancer and asynchronous double cancer within 3 years of progression-free period. However, the lesions correspondent to carcinoma in situ and intramucosal carcinoma curable by topical treatment are excluded)
- •3)Patients with active Hepatitis B or C. However, HBs antibody-positive or HBc antibody-positive but not active hepatitis with viral DNA load below sensitivity could be included in the study. HCV antibody-positive but not active hepatitis, could be included in the study.
- •4)The presence of evident interstitial pulmonary disease (idiopathic interstitial pneumonia, pneumoconiosis, irradiation pneumonitis, drug-induced pneumonitis, etc), that is clinically symptomatic or evident on chest X-ray or chest CT. however clinically stable opacity caused by radiotherapy could be enrolled in the study.
- •5)Patients with autoimmune disease or history of active autoimmune disease which requires systemic steroid treatment.
- •6)Patients receiving systemic steroids at doses higher than 10 mg/day of prednisolone equivalent for non- autoimmune diseases. Patients treated with immunosuppressive agents.
- •7)A history of severe hypersensitivity to carboplatin, nab-paclitaxel, or atezolizumab.
- •8)Symptomatic brain metastasis required for radiation therapy or surgical resection. Patients who are appropriately treated and neurologically stable for 7 days before the enrollment, and does not require an increase of steroid dose, can be enrolled.
- •9)Patients with carcinomatous meningitis.
- •10)Patients with pleural, ascites, or pericardial effusion which requires continuous drainage. If the effusion is controlled and the drain can be removed before the treatment, the patients can be enrolled in the study.
- •Cases with pleurodesis two weeks before enrollment can be enrolled.
- •11)Patients treated with palliative radiotherapy within 7 days prior to enrolment
- •12)Severe complications such as uncontrollable hypertension, diabetes mellitus, active gastrointestinal bleeding, or observed congestive heart failure, unstable angina, myocardial infarction within 6 months.
- •13)Pregnant, breastfeeding, or has possibility of pregnant and is unwilling to use contraception.
- •14)Patients who are different for the participation in the study by complication of mental disease or psychiatric symptom.
- •15)Any other patients who are regarded as unsuitable for this study by the investigators.
研究者
相似试验
已完成
2 期
A Phase II Study of Atezolizumab with Bevacizumab for Patients with Non-Small Cell Non-Squamous Cell Lung Cancer (At Be Study) (Investigator-Initiated Clinical Trial)non-small-cell lung cancerJPRN-jRCT2080223980Takashi Seto (Coordinating Investigator)38
进行中（未招募）
1 期
Study to assess efficacy of Atezolizumab in combination with Carboplatin Plus Pemetrexed in patients who are chemotherapy-naïve and have stage IV non-squamous non-small cell lung cancer with asymptomatic brain metastases (ATEZO-BRAIN)Atezolizumab combined with carboplatin and pemetrexedMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2017-005154-11-ESSpanish Lung Cancer Group (SLCG/GECP)40
进行中（未招募）
1 期
Phase II study of Atezolizumab plus Tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal.Squamous cell carcinoma of the anal canalMedDRA version: 26.0Level: LLTClassification code: 10084945Term: Basaloid squamous cell carcinoma of the anal canal Class: 100000004848CTIS2023-509485-38-00Grupo Espanol Multidisciplinar En Cancer Digestivo45
尚未招募
Unknown
A single-arm phase II trial of Atezolizumab and Bevacizumab with combined radiotherapy in advanced hepatocellular carcinoma with portal vein invasioKCT0008733Yonsei University Health System, Severance Hospital51
进行中（未招募）
1 期
Atezolizumab and bevacizumab study for non small cell lung cancer patients with high-intermediate tumour mutation burdeon small cell lung cancerMedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004654-17-ESFundación GECP102